Buy Keytruda (pembrolizumab)
$2,050.00
Keytruda (pembrolizumab) is a medication used for the treatment of advanced melanoma, metastatic nonsquamous NSCLC, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), recurrent classical Hodgkin Lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, solid tumours having the biomarkers MSI-H or dMMR, recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, triple-negative breast cancer.
Description
What is Keytruda (pembrolizumab) for?
Keytruda (pembrolizumab) is a monoclonal antibody (immunotherapy) indicated for the treatment of people with:
- advanced (unresectable or metastatic) melanoma
- metastatic nonsquamous NSCLC as first-line treatment in combination with pemetrexed and carboplatin
- recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- recurrent classical Hodgkin Lymphoma (cHL)
- locally advanced or metastatic urothelial carcinoma
- solid tumours having the biomarkers MSI-H or dMMR
- recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- advanced renal cell carcinoma (RCC).
- locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
It is available as a powder for intravenous infusion (drip) containing 100mg of pembrolizumab per vial.
Note: Keytruda (pembrolizumab) is currently only available in 100mg form (100mg/4ml). There used to be a 50mg presentation but this has been discontinued as of March 15th, 2019.
How does Keytruda (pembrolizumab) work?
Keytruda (pembrolizumab) is a monoclonal antibody, a type of protein that has been designed to recognise and attach to a specific structure (called an antigen) that is found in certain cells in the body.
Keytruda (pembrolizumab) has been designed to attach to and block a receptor called ‘programmed cell death-1’ (PD-1), which switches off the activity of certain cells of the immune system (the body’s natural defences) called T cells. By blocking PD-1, pembrolizumab prevents PD-1 from switching off these immune cells, thereby increasing the ability of the immune system to kill cancer cells.
Additional information
| Package | 1 vial of powder for infusion / 100 mg per vial |
|---|
Benjamin C. Ramirez –
Keytruda has been a game-changer in my battle against lung cancer. When conventional treatments failed to yield significant results, I turned to Keytruda with cautious optimism. The results were nothing short of astounding. Not only did Keytruda halt the progression of my cancer, but it also shrunk the tumors, offering me a renewed sense of hope and vitality. The side effects, though present, were manageable compared to the debilitating effects of chemotherapy. Keytruda’s immunotherapy approach seems tailor-made for my body, effectively targeting cancer cells while leaving healthy cells unharmed. It’s not just a medication; it’s a lifeline for those of us navigating the treacherous waters of cancer treatment. I am eternally grateful to the scientists and researchers behind Keytruda for giving me a chance to reclaim my life.